CAS 138778-28-6

Siratiazem

Description:

Siratiazem, identified by its CAS number 138778-28-6, is a chemical compound that belongs to the class of benzothiazepines. It is primarily recognized for its pharmacological properties, particularly as a calcium channel blocker, which makes it useful in the treatment of cardiovascular conditions such as hypertension and angina. The compound exhibits a unique structure characterized by a benzothiazepine core, which contributes to its ability to modulate calcium ion influx in cardiac and smooth muscle cells. Siratiazem's mechanism of action involves the inhibition of calcium channels, leading to vasodilation and reduced myocardial oxygen demand. Additionally, it may possess antiarrhythmic properties, making it beneficial in managing certain heart rhythm disorders. The compound's solubility, stability, and bioavailability are important factors that influence its therapeutic efficacy. As with many pharmaceuticals, understanding its pharmacokinetics and potential side effects is crucial for safe and effective use in clinical settings.

Formula: C₂₄H₃₀N₂O₄S

InChI: InChI=1/C24H30N2O4S/c1-16(2)25(4)14-15-26-20-8-6-7-9-21(20)31-23(22(24(26)28)30-17(3)27)18-10-12-19(29-5)13-11-18/h6-13,16,22-23H,14-15H2,1-5H3/t22-,23+/m1/s1

Synonyms:

• Siratiazem [INN]
• (+)-(2S,3S)-2,3-Dihydro-3-hydroxy-5-(2-(isopropylmethylamino)ethyl)-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate (ester)
• Unii-Chj1X6Ag9F
• 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-2,3-dihydro-2-(4-methoxyphenyl)-5-(2-(methyl(1-methylethyl)amino)ethyl)-, cis-(+)-
• (2S,3S)-2-(4-methoxyphenyl)-5-{2-[methyl(propan-2-yl)amino]ethyl}-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate

Siratiazem

CAS: 138778-28-6

Siratiazem is a calcium-channel blocker that is used for the treatment of cardiac arrhythmia and hypertension, as well as for the prevention of congestive heart failure. Siratiazem is a prodrug that is converted to its active form by hydrolysis in the liver. It binds to the L-type calcium channels in cardiac muscle cells, thereby blocking calcium influx and decreasing the excitability of these cells. This drug has been shown to be effective in phase 1 clinical trials, with no major adverse effects. Siratiazem can cause symptoms such as nausea, vomiting, diarrhea, or constipation and may also have effects on insulin resistance and ventricular dysfunction.

Formula: C₂₄H₃₀N₂O₄S

Purity: Min. 95%

Molecular weight: 442.57 g/mol

Ref: 3D-FS170126